183 related articles for article (PubMed ID: 23266047)
1. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
[TBL] [Abstract][Full Text] [Related]
2. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer.
Sand M; Gambichler T; Skrygan M; Sand D; Scola N; Altmeyer P; Bechara FG
Cancer Invest; 2010 Jul; 28(6):649-53. PubMed ID: 20210522
[TBL] [Abstract][Full Text] [Related]
3. Dicer, Drosha, and outcomes in patients with ovarian cancer.
Merritt WM; Lin YG; Han LY; Kamat AA; Spannuth WA; Schmandt R; Urbauer D; Pennacchio LA; Cheng JF; Nick AM; Deavers MT; Mourad-Zeidan A; Wang H; Mueller P; Lenburg ME; Gray JW; Mok S; Birrer MJ; Lopez-Berestein G; Coleman RL; Bar-Eli M; Sood AK
N Engl J Med; 2008 Dec; 359(25):2641-50. PubMed ID: 19092150
[TBL] [Abstract][Full Text] [Related]
4. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Dicer predicts poor survival in colorectal cancer.
Faber C; Horst D; Hlubek F; Kirchner T
Eur J Cancer; 2011 Jun; 47(9):1414-9. PubMed ID: 21345667
[TBL] [Abstract][Full Text] [Related]
6. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
7. Expression of Dicer and Drosha in triple-negative breast cancer.
Passon N; Gerometta A; Puppin C; Lavarone E; Puglisi F; Tell G; Di Loreto C; Damante G
J Clin Pathol; 2012 Apr; 65(4):320-6. PubMed ID: 22259182
[TBL] [Abstract][Full Text] [Related]
8. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
[TBL] [Abstract][Full Text] [Related]
9. A low Dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma.
Kawahara K; Nakayama H; Nagata M; Yoshida R; Hirosue A; Tanaka T; Nakagawa Y; Matsuoka Y; Kojima T; Takamune Y; Yoshitake Y; Hiraki A; Shinohara M
J Oral Pathol Med; 2014 May; 43(5):350-6. PubMed ID: 24325353
[TBL] [Abstract][Full Text] [Related]
10. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma.
Guo X; Liao Q; Chen P; Li X; Xiong W; Ma J; Li X; Luo Z; Tang H; Deng M; Zheng Y; Wang R; Zhang W; Li G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):49-56. PubMed ID: 21953080
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of dicer and mir-155 expression in liposarcoma.
Vincenzi B; Iuliani M; Zoccoli A; Pantano F; Fioramonti M; De Lisi D; Frezza AM; Rabitti C; Perrone G; Onetti Muda A; Russo A; Giordano A; Santini D; Dei Tos AP; Tonini G
Oncotarget; 2015 Apr; 6(12):10586-91. PubMed ID: 25888631
[TBL] [Abstract][Full Text] [Related]
12. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Gui Y; Cai Z
J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
[TBL] [Abstract][Full Text] [Related]
13. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.
Tchernitsa O; Kasajima A; Schäfer R; Kuban RJ; Ungethüm U; Györffy B; Neumann U; Simon E; Weichert W; Ebert MP; Röcken C
J Pathol; 2010 Nov; 222(3):310-9. PubMed ID: 20726036
[TBL] [Abstract][Full Text] [Related]
15. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
16. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
[TBL] [Abstract][Full Text] [Related]
17. Loss of Dicer expression is associated with breast cancer progression and recurrence.
Khoshnaw SM; Rakha EA; Abdel-Fatah TM; Nolan CC; Hodi Z; Macmillan DR; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Sep; 135(2):403-13. PubMed ID: 22821364
[TBL] [Abstract][Full Text] [Related]
18. EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma.
Zhang Z; Zhang G; Kong C; Bi J; Gong D; Yu X; Shi D; Zhan B; Ye P
Tumour Biol; 2015 Jul; 36(7):5071-9. PubMed ID: 25656609
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
20. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
Ma Y; Zhang P; Wang F; Zhang H; Yang J; Peng J; Liu W; Qin H
Gut; 2012 Oct; 61(10):1447-53. PubMed ID: 22052060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
